Table 2.
Clinical characteristics of patients in the training set and validation set for predicting prognosis.
| Characteristic | Our Study (Training Set) |
TCGA (Validation Set) |
p-Value | |
|---|---|---|---|---|
| Number of patients | 43 | 208 | - | |
| Age (mean years, range) | 56 (37–77) | 59 (31–87) | 0.073 | |
| Progression-free survival (median months, 95% confidence interval) |
22.8 (18.4–32.8) | 17.5 (14.9–19.9) | 0.089 | |
| Overall survival (median months, 95% confidence interval) |
Not reached | 45.4 (41.9–53.9) | 0.0012 | |
| Stage | III | 38 (88.4%) | 183 (88.0%) | 1.0 |
| IV | 5 (11.6%) | 25 (12.0%) | ||
|
BRCA1/2 mutation |
Germline | 14 (32.6%) | 1 (0.5%) | 9.5 × 10−6 |
| Somatic | 3 (7.0%) | 9 (4.3%) | ||
| Germline + somatic | 0 | 2 (1.0%) | ||
| No mutation | 25 (58.1%) | 122 (58.7%) | ||
| Not available | 1 (2.3%) | 74 (35.6%) | ||